[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@kaitan000](/creator/twitter/kaitan000) "Recent concerns around rising stablecoin adoption the proposed OBBB XXX% tax on remittances and insider selling activity/Naspers sale may be overblown. $RELY is currently trading near its all-time low EV/sales multiple of approximately 2.2x despite projected FY2025 revenue growth of XX% and a potential inflection toward profitability in the coming quarters. Given this setup I believe the risk-reward profile is skewed favorably to the upside"  [@kaitan000](/creator/x/kaitan000) on [X](/post/tweet/1946191229957628119) 2025-07-18 12:52:02 UTC XXX followers, XXX engagements "Why $DCTH may continue to rise in the future. Financial Guidance for 2025: - Revenue: Delcath projects total revenue from HEPZATO KIT and CHEMOSAT to be $94$98 million a 150%+ increase from 2024s $XXXX million driven by U.S. commercial expansion and increased adoption of HEPZATO for metastatic uveal melanoma (mUM). - Gross Margins: Expected to range between XX% and XX% reflecting strong profitability potential. - EBITDA and Cash Flow: Positive adjusted EBITDA and cash flow are anticipated in each quarter of 2025 supported by revenue growth and operational efficiencies. Q1 2025 reported a"  [@kaitan000](/creator/x/kaitan000) on [X](/post/tweet/1940768830462255343) 2025-07-03 13:45:21 UTC XXX followers, 4841 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@kaitan000
"Recent concerns around rising stablecoin adoption the proposed OBBB XXX% tax on remittances and insider selling activity/Naspers sale may be overblown. $RELY is currently trading near its all-time low EV/sales multiple of approximately 2.2x despite projected FY2025 revenue growth of XX% and a potential inflection toward profitability in the coming quarters. Given this setup I believe the risk-reward profile is skewed favorably to the upside"
@kaitan000 on X 2025-07-18 12:52:02 UTC XXX followers, XXX engagements
"Why $DCTH may continue to rise in the future. Financial Guidance for 2025: - Revenue: Delcath projects total revenue from HEPZATO KIT and CHEMOSAT to be $94$98 million a 150%+ increase from 2024s $XXXX million driven by U.S. commercial expansion and increased adoption of HEPZATO for metastatic uveal melanoma (mUM). - Gross Margins: Expected to range between XX% and XX% reflecting strong profitability potential. - EBITDA and Cash Flow: Positive adjusted EBITDA and cash flow are anticipated in each quarter of 2025 supported by revenue growth and operational efficiencies. Q1 2025 reported a" @kaitan000 on X 2025-07-03 13:45:21 UTC XXX followers, 4841 engagements